Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Miscellaneous and experimental agents

J Y Reginster1

  • 1Unité d'Exploration du Métabolisme Osseux et du Cartilage ArticulaireUniversité de Liége, Belgium.

The American Journal of the Medical Sciences
|January 1, 1997
PubMed
Summary

New osteoporosis treatments are under investigation, including estrogen antagonist/agonists, growth hormone, ipriflavone, parathyroid peptides, and strontium. These aim to improve bone density and prevent fractures in postmenopausal women.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: Bobelyak M, Vaculik J, Stepan JJ. Bone mineral density assessment using Radiofrequency Echographic Mult Spectrometry (REMS) in patients before and after total hip replacement, Osteoporos Int 2025;https://doi.org/10.1007/s00198-025-07685-w and Re: Pocock N, Chan D. Editorial: Is REMS-BMD truly a measured parameter? A call for transparency and technical clarification, Osteoporos Int 2025;https://doi.org/10.1007/s00198-025-07699-4.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Latin American patients' perceptions on osteoporosis diagnosis and treatment: The IOF Patient Advisory Group in Latin America.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Patient perceptions of osteoporosis management: a qualitative pilot study by a patient advisory group.

Archives of osteoporosis·2025
Same author

Assessing gait parameters with accelerometer-based methods to identify older adults at risk of falls: a systematic review.

European geriatric medicine·2021
Same author

Relationship between smoking and the incidence of sarcopenia: The SarcoPhAge cohort.

Public health·2021
Same author

Osteoporosis in Frail Older Adults: Recommendations for Research from the ICFSR Task Force 2020.

The Journal of frailty & aging·2021

Area of Science:

  • Bone biology and pharmacology
  • Endocrinology and metabolic diseases
  • Geriatric medicine

Background:

  • Current osteoporosis treatments have limitations in fracture prevention.
  • Postmenopausal bone loss and established osteoporosis require novel therapeutic strategies.
  • Investigational compounds are being developed to address unmet needs in osteoporosis management.

Purpose of the Study:

  • To review current and emerging therapeutic approaches for postmenopausal bone loss and osteoporosis.
  • To evaluate the potential benefits and risks of various investigational compounds.
  • To identify promising alternatives to hormonal replacement therapy and other established treatments.

Main Methods:

  • Review of current literature on osteoporosis treatments.

Related Experiment Videos

  • Analysis of ongoing clinical trials for novel compounds.
  • Evaluation of pharmacological mechanisms of action and preliminary efficacy data.

    • Main Results:

    • Anabolic steroids show limited benefit and significant risks for osteoporosis.
    • Estrogen antagonist/agonists show promise as alternatives to hormone replacement therapy.
    • Ipriflavone, parathyroid peptides, and strontium demonstrate potential in increasing bone mass and density.
    • Growth hormone and insulin-like growth factors require further investigation.
    • Hip protectors may reduce hip fracture incidence.

    Conclusions:

    • Several novel compounds show promise for osteoporosis treatment, with estrogen antagonist/agonists being a prominent alternative.
    • Further large-scale studies are needed to confirm the efficacy and safety of ipriflavone, parathyroid peptides, and strontium.
    • Continued research into growth hormone, insulin-like growth factors, and hip protectors is warranted.